Validation of gallbladder absorbed radiation dose reduction simulation: human dosimetry of [18F]fluortriopride

Background[F-18]Fluortriopride (FTP) was developed as a dopamine D3-selective radiotracer, thought to be important to neurobiological reward pathways and implicated in drug addiction, Parkinson's disease, and schizophrenia. Preclinical radiation dosimetry studies found the gallbladder wall received the highest dose. A gallbladder dose reduction intervention was simulated using a novel reduction model for healthy adults following fatty-meal consumption. The goals of this study were to assess whole body FTP human dosimetry and determine the feasibility of reducing absorbed dose to the gallbladder wall.ResultsEffective dose without a fatty meal was 0.0220.002mSv/MBq (+/- standard deviation) with highest organ dose of 0.436 +/- 0.178mSv/MBq to the gallbladder wall (n=10). Predicted gallbladder dose reduction with fatty meal consumed was 67.4% (n=10). Meal consumption by four repeat volunteers decreased average gallbladder dose by 71.3% (n=4) compared to the original ten volunteers.Conclusions Observed effective doses were adequately low to continue studying FTP uptake in humans. Validated dosimetry simulations indicate up to a 71% reduction in gallbladder dose can be achieved by employing intrinsic physiology to contract the gallbladder via fatty meal ingestion. This methodology for predicting gallbladder absorbed dose reduction from fatty meal consumption can be applied to other radiopharmaceuticals and radiotherapies.